HC Wainwright Forecasts Genelux’s Q3 Earnings (NASDAQ:GNLX)

Genelux Corporation (NASDAQ:GNLX) – Research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Genelux in a research note issued to investors on Friday, May 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.21). The consensus estimate for Genelux’s current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Genelux’s Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS and FY2027 earnings at ($0.75) EPS.

A number of other research analysts also recently weighed in on GNLX. Wall Street Zen downgraded Genelux from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research note on Tuesday, April 21st. Finally, Benchmark cut their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 20th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Genelux Price Performance

GNLX opened at $2.90 on Tuesday. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The business has a 50-day moving average of $2.65 and a 200-day moving average of $3.70. The company has a market capitalization of $130.04 million, a PE ratio of -3.41 and a beta of 0.51.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02).

Insider Buying and Selling at Genelux

In other news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the sale, the director owned 482,784 shares of the company’s stock, valued at approximately $1,400,073.60. This trade represents a 2.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.50% of the company’s stock.

Institutional Trading of Genelux

Several institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Genelux in the 1st quarter valued at $190,000. Hudson Bay Capital Management LP bought a new position in Genelux in the 4th quarter valued at $165,000. Align Financial LLC bought a new position in Genelux in the 4th quarter valued at $123,000. Balyasny Asset Management L.P. bought a new position in Genelux in the 4th quarter valued at $94,000. Finally, Marshall Wace LLP bought a new position in Genelux in the 2nd quarter valued at $92,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Key Stories Impacting Genelux

Here are the key news stories impacting Genelux this week:

• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate for Genelux to a loss of $0.81 per share from $0.79, signaling a slightly weaker full-year profit outlook. Genelux stock and analyst coverage
• Negative Sentiment: Brookline Capital Markets cut its FY2026 EPS estimate to a loss of $0.79 per share from $0.69, another sign that analysts expect deeper losses than previously modeled. Genelux stock and analyst coverage
• Negative Sentiment: Brookline also reduced Q2 2026 and Q3 2026 EPS estimates to losses of $0.19 and $0.20, respectively, while HC Wainwright trimmed Q4 2026 expectations to a $0.20 loss, reinforcing the view that profitability remains distant. Genelux stock and analyst coverage
• Neutral Sentiment: HC Wainwright slightly raised its Q3 2026 EPS estimate to a $0.20 loss from $0.21, a modest change that does not materially alter the broader negative earnings picture. Genelux stock and analyst coverage
• Neutral Sentiment: Short-interest data showed no meaningful change in the share count, so it is unlikely to be a major driver of trading today. Genelux stock short interest

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.